Frontier Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

BOSTON and SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced that Chris Varma, Ph.D., co-founder, chair, and chief executive officer of Frontier Medicines, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:30 p.m. PST.

About Frontier Medicines
Frontier Medicines is a clinical-stage precision medicine company pioneering groundbreaking medicines to transform treatment for genetically defined patient populations, starting with oncology and immunology. Our proprietary chemoproteomics-powered drug discovery engine, the Frontier™ Platform, leverages covalent chemistry and machine learning to unlock difficult-to-drug, disease-causing proteins for drug development. Today, we are advancing a diversified pipeline of wholly owned precision medicines against the most critical drivers of cancer and high-value immunology programs. For more information, please visit www.frontiermeds.com. Follow Frontier on LinkedIn.

Media Contact
pr@frontiermeds.com


Primary Logo

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  236.65
-5.95 (-2.45%)
AAPL  259.96
-1.09 (-0.42%)
AMD  223.60
+2.63 (1.19%)
BAC  52.48
-2.06 (-3.78%)
GOOG  336.31
-0.12 (-0.04%)
META  615.52
-15.57 (-2.47%)
MSFT  459.38
-11.29 (-2.40%)
NVDA  183.16
-2.65 (-1.43%)
ORCL  193.61
-8.68 (-4.29%)
TSLA  439.20
-8.00 (-1.79%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.